Vaccine Trials

RV 172

“A phase I/II clinical trial to evaluate the safety and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine boosted by a multiclade HIV-1 recombinant adenovirus-5 vector vaccine in HIV uninfected adult volunteers in East Africa”

Purpose

The objectives of the study were to evaluate the safety and immunogenicity of a multiclade A, B and C HIV DNA prime (VRC-HIVDNA016-00-VP) boosted with a multiclade A, B and C recombinant Adenovirus type 5 vector (VRC-HIVADV014-00-VP). The vaccine was provided by the NIH Vaccine Research Center (VRC) consisting of a multiclade A, B and C HIV DNA prime (VRC-HIVDNA016-00-VP) boosted with a multiclade A, B and C recombinant Adenovirus type 5 vector (VRC-HIVADV014-00-VP).

Team: Leonard Maboko (Principal Investigator), Mirjam Schunk, Arne Kroidl (Clinical Research Coordinator)

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya Hakika kwa pamoja tunaweza kutokomeza Kifua Kikuu nchini Tanzania @wizara_afyatz @elimuyaafya @ummymwalimu… https://t.co/Lq2bPfT0aI
2h • reply • retweet • favorite
NIMRMbeya Congratulation to our Dr. Wilbert Mbuya @Wilylarry for being awarded INSIGHT Fogatry @insight_fogarty Postdoc fello… https://t.co/n8i9J35K5H
2h • reply • retweet • favorite
NIMRMbeya RT @UNAIDS: Today is #WorldTBDay. People living with HIV are up to 18 times more likely to develop TB disease compared to people without H…
4h • reply • retweet • favorite
NIMRMbeya RT @Kcmc1971: @wizara_afyatz @worldtbday #EndTB #WorldTBDay2023 https://t.co/5OtoJ4QY5U
4h • reply • retweet • favorite
NIMRMbeya RT @TBSequel: TB Sequel team is working closely with international organizations and donors like USAID, WHO and Global Find to raise awaren…
4h • reply • retweet • favorite
© 2017 NIMR - Mbeya Medical Research Center